Supplementary Table 1. Secondary efficacy outcomes (per-protocol set): change[a] from baseline at week 24

Variable	Statistics	Rosuvastatin ($n=45$)	Rosuvastatin/ Ezetimibe ($n=41$)	LS mean difference (SE)	95% CI	P value
Calculated LDL-C	Mean±SD	−62.27±27.36	−77.85±33.27			
	P value	<0.0001[b]	<0.0001[b]			
	LS mean (SE)[c]	−72.92 (8.34)	−82.78 (8.37)	−9.86 (4.89)	−19.59 to −0.13	0.0472
HDL-C	Mean±SD	1.07±6.97	1.98±9.19			
	P value	0.5240	0.1761			
	LS mean (SE)	−2.50 (2.93)	−0.77 (2.92)	1.73 (1.71)	−1.68 to 5.14	0.3153
Triglyceride	Mean±SD	−52.76±84.15	−44.83±76.71			
	P value	<0.0001	0.0006			
	LS mean (SE)	−40.02 (22.88)	−40.75 (22.88)	−0.74 (13.21)	−27.02 to 25.55	0.9557
Non-HDL-C	Mean±SD	−73.18±29.26	−86.78±37.33			
	P value	<0.0001	<0.0001			
	LS mean (SE)	−80.29 (9.55)	−90.06 (9.62)	−9.77 (5.55)	−20.81 to 1.27	0.0820
ApoB	Mean±SD	−47.59±21.27	−57.55±25.59			
	P value	<0.0001	<0.0001			
	LS mean (SE)	−54.77 (6.98)	−61.90 (7.04)	−7.14 (4.06)	−15.21 to 0.93	0.0823
HbA1c	Mean±SD	0.50±0.99	0.59±0.92			
	P value	0.0016	<0.0001			
	LS mean (SE)	−0.65 (0.36)	−0.57 (0.37)	0.08 (0.20)	−0.31 to 0.47	0.6899
FPG	Mean±SD	14.59±39.60	5.61±38.44			
	P value	0.0142	0.3557			
	LS mean (SE)	−2.14 (14.51)	−10.40 (14.63)	−8.25 (8.36)	−24.89 to 8.38	0.3265
HOMA-IR	Mean±SD	0.67±5.24	0.35±2.80			
	P value	0.9588	0.0265			
	LS mean (SE)	1.69 (1.59)	1.29 (1.60)	−0.40 (0.93)	−2.24 to 1.45	0.6697
HOMA-β	Mean±SD	−18.44±58.64	9.24±26.50			
	P value	0.0305	0.0312			
	LS mean (SE)	−5.63 (12.12)	11.51 (12.28)	17.13 (7.13)	2.95 to 31.31	0.0185

LS, least square; SE, standard error; CI, confidence interval; SD, standard deviation; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ApoB, apolipoprotein B; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function.

[a]Change = (value at week 24–baseline value) of each variable, [b]Difference between baseline and week 24 in each group, [c]Difference between control and treatment group (analysis of covariance [ANCOVA] using baseline value and HbA1c level [<9%, ≥9%] as covariate).